Status:

COMPLETED

Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines

Lead Sponsor:

Sanofi

Conditions:

Diphtheria

Tetanus

Eligibility:

All Genders

6-19 years

Phase:

PHASE4

Brief Summary

The present clinical study will assess the immunogenicity and reactogenicity of the subsequent administration of Aventis Pasteur's DTacP-IPV//PRP\~T combined vaccine (PENTAVAC™/PENTAXIM), as a three-d...

Detailed Description

Open, randomized, multicentric, controlled trial. Infants will be randomly allocated in one of the two study groups as follows: Group A: 212 subjects will receive the PENTAXIM™ vaccine at 6, 10 and 1...

Eligibility Criteria

Inclusion

  • Informed consent signed by one or both parent(s) and/or by a legally accepted representative prior to the first study intervention
  • Healthy male or female newborn
  • Age ranging from birth to 48 hours of life (included)
  • Birth weight \>2.5 kg and gestational age \>37 weeks
  • Born to HBs antigen-negative mother

Exclusion

  • Known previous therapy of the mother with cadaveric pituitary derived human growth hormone
  • Infant presently enrolled or scheduled to be enrolled in another clinical trial
  • Infant with moderate or severe illness, mainly infectious diseases
  • Infant with fever (rectal temperature \> 38°C or axillary temperature \> 37.5°C)
  • Infant with severe congenital defects or abnormalities
  • Uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection.
  • Known immunological deficiency (including a known HIV seropositive mother)
  • Administration of vaccine since birth (other than BCG)
  • Previous or planned administration of immunosuppressive therapy, immunoglobulins and /or any blood-derived products (inhaled and topical corticoids are allowed)

Key Trial Info

Start Date :

October 1 2003

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2006

Estimated Enrollment :

387 Patients enrolled

Trial Details

Trial ID

NCT00254917

Start Date

October 1 2003

End Date

February 1 2006

Last Update

April 16 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Manila, Philippines

Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines | DecenTrialz